Swiss National Bank
TEVA icon

Swiss National Bank’s Teva Pharmaceuticals TEVA Stock Holding History

Swiss National Bank’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140M Sell
4,121,700
-106,200
-3% -$3.54M 0.07% 229
2026
Q1 		$127M Buy
4,227,900
+941,700
+29% +$30.3M 0.07% 230
2025
Q4 		$103M Sell
3,286,200
-142,300
-4% -$3.51M 0.06% 256
2025
Q3 		$69.3M Sell
3,428,500
-188,000
-5% -$3.3M 0.04% 344
2025
Q2 		$60.6M Buy
3,616,500
+486,100
+16% +$7.84M 0.04% 384
2025
Q1 		$48.1M Buy
3,130,400
+2,500
+0.1% +$44.7K 0.03% 415
2024
Q4 		$68.9M Sell
3,127,900
-215,000
-6% -$3.91M 0.05% 333
2024
Q3 		$60.2M Buy
3,342,900
+15,300
+0.5% +$268K 0.04% 385
2024
Q2 		$54.1M Sell
3,327,600
-17,200
-0.5% -$265K 0.04% 385
2024
Q1 		$47.2M Sell
3,344,800
-156,900
-4% -$1.98M 0.03% 440
2023
Q4 		$36.6M Sell
3,501,700
-122,100
-3% -$1.14M 0.03% 510
2023
Q3 		$37M Sell
3,623,800
-360,500
-9% -$3.36M 0.03% 486
2023
Q2 		$30M Sell
3,984,300
-417,100
-9% -$3.38M 0.02% 570
2023
Q1 		$39M Sell
4,401,400
-108,600
-2% -$1.07M 0.03% 522
2022
Q4 		$41.1M Sell
4,510,000
-206,093
-4% -$1.8M 0.03% 491
2022
Q3 		$38.1M Buy
4,716,093
+27,700
+0.6% +$245K 0.03% 516
2022
Q2 		$35.3M Buy
4,688,393
+31,700
+0.7% +$276K 0.02% 539
2022
Q1 		$43.7M Buy
4,656,693
+353,300
+8% +$2.95M 0.02% 532
2021
Q4 		$34.5M Sell
4,303,393
-249,900
-5% -$2.26M 0.02% 573
2021
Q3 		$44.3M Sell
4,553,293
-115,000
-2% -$1.08M 0.03% 527
2021
Q2 		$46.2M Buy
4,668,293
+347,894
+8% +$3.68M 0.03% 532
2021
Q1 		$49.9M Buy
4,320,399
+98,100
+2% +$1.12M 0.03% 492
2020
Q4 		$40.7M Sell
4,222,299
-102,300
-2% -$980K 0.03% 520
2020
Q3 		$39M Sell
4,324,599
-77,400
-2% -$819K 0.03% 484
2020
Q2 		$54.3M Buy
4,401,999
+94,500
+2% +$1.07M 0.05% 381
2020
Q1 		$38.7M Buy
4,307,499
+486,000
+13% +$4.98M 0.04% 410
2019
Q4 		$37.5M Sell
3,821,499
-207,600
-5% -$1.85M 0.04% 446
2019
Q3 		$27.7M Buy
4,029,099
+44,000
+1% +$337K 0.03% 513
2019
Q2 		$36.8M Buy
3,985,099
+413,800
+12% +$4.99M 0.04% 445
2019
Q1 		$56M Buy
3,571,299
+37,200
+1% +$656K 0.06% 320
2018
Q4 		$54.5M Buy
3,534,099
+31,300
+0.9% +$642K 0.07% 280
2018
Q3 		$75.5M Sell
3,502,799
-184,100
-5% -$4.27M 0.08% 251
2018
Q2 		$89.7M Buy
3,686,899
+298,600
+9% +$6.09M 0.1% 212
2018
Q1 		$57.9M Sell
3,388,299
-135,200
-4% -$2.64M 0.07% 292
2017
Q4 		$66.8M Buy
3,523,499
+32,000
+0.9% +$481K 0.07% 282
2017
Q3 		$61.5M Buy
3,491,499
+17,900
+0.5% +$403K 0.07% 290
2017
Q2 		$115M Buy
3,473,599
+33,448
+1% +$1.04M 0.14% 163
2017
Q1 		$110M Sell
3,440,151
-190,100
-5% -$6.49M 0.14% 166
2016
Q4 		$132M Buy
+3,630,251
New +$145M 0.21% 108

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Swiss National Bank's TEVA Position: Q2 2026 in Review

Swiss National Bank reduced its Teva Pharmaceuticals (TEVA) stake by 2.5% in Q2 2026, selling an estimated $3.54M and leaving 4,121,700 shares worth $140M. The position accounts for 0.07% of the portfolio, ranked #229.

Swiss National Bank first reported a position in TEVA in Q4 2016 and has held it in 39 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Swiss National Bank held 4,121,700 shares of Teva Pharmaceuticals worth $140M as of Q2 2026.
  • Swiss National Bank sold 106,200 Teva Pharmaceuticals shares in Q2 2026, an estimated $3.54M.
  • Teva Pharmaceuticals made up 0.07% of Swiss National Bank's portfolio in Q2 2026, its #229 holding.
  • Swiss National Bank first reported a position in Teva Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.